Business Context and Reporting Period
This Form 8-K is a current report filed by Manhattan Pharmaceuticals, Inc. (noted as TG THERAPEUTICS, INC. in metadata) on June 23, 2011. The filing addresses corporate governance changes and a significant capital structure adjustment involving a reverse stock split.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate actions and share structure adjustments.
Material Changes
- Board Departure: Timothy McInerney resigned from the Board of Directors effective June 23, 2011.
- Reverse Stock Split: The Board approved a 1-for-50 reverse stock split, authorized by stockholders at the May 20, 2011 Annual Meeting. This reduces approximately 129.8 million pre-split shares to approximately 2.6 million post-split shares.
- Shareholder Impact: No fractional shares will be issued; holders of non-divisible amounts will receive one whole share. Percentage ownership remains substantially unchanged.
- Trading Adjustments: The ticker symbol will temporarily change to "MHAND" for 20 trading days starting around July 8, 2011, before reverting to "MHAN".
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific risks or contingencies beyond the procedural details of the stock split and board resignation. The company expects the Financial Industry Regulatory Authority (FINRA) approval process to be completed on or about July 8, 2011.
Investor Verification Checklist
- Confirm the exact date post-split trading begins (expected July 8, 2011).
- Verify the temporary ticker symbol change to "MHAND" and the subsequent reversion to "MHAN".
- Check for instructions from the transfer agent, Continental Stock Transfer and Trust Company, regarding certificate exchange.
- Review adjustments to outstanding equity awards, warrants, and convertible notes to ensure they reflect the 1-for-50 split ratio.